Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03972306 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
NCT03972306 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 134 participants.
The verdict
NCT03972306, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS).
Interventions
- DRUG Ocrelizumab
- DRUG rHuPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2025-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03972306
The ClinicalTrials.gov registry entry for NCT03972306 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ocrelizumab is the first listed.
NCT03972306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03972306 about?
NCT03972306 is a clinical study titled "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis". This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS).
What is the current status of trial NCT03972306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2019-08-12. Estimated completion is 2025-06-03.
What interventions are being tested in trial NCT03972306?
The interventions under investigation include: Ocrelizumab (DRUG), rHuPH20 (DRUG).
Who is sponsoring clinical trial NCT03972306?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.